Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134 PHASE3 COMPLETED Results posted

The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticanse propionate/salmeterol (250/50mcg) twice-daily on lung function, COPD-related health status assessments and safety in COPD subjects.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE3
Status	COMPLETED
Enrolment	617
Start date	Tue Jan 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

• Umeclidinium bromide 62.5mcg
• Umeclidinium bromide 125mcg
• Fluticasone propionate 250mcg/Salmeterol 50mcg
• Placebo

Countries

Canada, United States, Germany, South Korea